Form 6-K GENETIC TECHNOLOGIES For: Jul 09
FORM 6-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
dated July 9, 2015
Commission File Number 0-51504
GENETIC TECHNOLOGIES LIMITED
(Exact Name as Specified in its Charter)
N/A
(Translation of Registrants Name)
60-66 Hanover Street
Fitzroy
Victoria 3065 Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x |
Form 40-F o |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o |
No x |
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: July 9, 2015
|
GENETIC TECHNOLOGIES LIMITED | |
|
|
|
|
|
|
|
By: |
/s/ Bronwyn Christie |
|
|
Name: Bronwyn Christie |
|
|
Title: Company Secretary |
Exhibit 99.1
ASX ANNOUNCEMENT
09 July 2015
Appointment of Joint Company Secretary
Melbourne, Australia, 09 July 2015: Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, Company) is pleased to announce the appointment of Mr. Brian Manuel as Joint Company Secretary, effective immediately.
Mr. Manuel joined the Company as Chief Financial Officer on 15 June 2015. He is a Fellow Chartered Accountant and a Fellow of the Governance Institute of Australia. Of his 25 plus years of experience, more than a decade has been at the CFO level for companies listed on the ASX including the Biotech Company Cellestis Ltd, as the CFO and Company Secretary until its acquisition in 2011.
He brings broad business acumen to the Company in addition to his strong foundation in finance, IT and corporate governance.
FOR FURTHER INFORMATION PLEASE CONTACT
Mr. Eutillio Buccilli |
Candice Knoll (USA) |
Executive Director & Chief Executive Officer |
Blueprint Life Science Group |
Genetic Technologies Limited |
+1 (415) 375 3340, Ext. 105 |
+ 61 3 8412 7050 |
|
About Genetic Technologies Limited
Genetic Technologies is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage womens health. The Companys lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGenplus® improves upon the predictive power of the first generation BREVAGen test and is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. BREVAGenplus® expands the application of BREVAGen from Caucasian women to include African-Americans and Hispanics, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer.
The Company has successfully launched the first generation BREVAGen test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. and the addition of BREVAGenplus®, launched in October 2014, significantly expands the applicable market. The Company markets BREVAGenplus® to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons).
For more information, please visit www.brevagenplus.com and www.phenogensciences.com.
Safe Harbor Statement
Any statements in this press release that relate to the Companys expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Companys actual results may differ materially from expected results. Additional risks associated with Genetic Technologies business can be found in its periodic filings with the SEC.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Genetic Technologies (GENE) Announces $2 Million Registered Direct Offering
- Avis Budget Group to Announce First Quarter 2024 Results on May 1st
- Biosenta Announces Private Placement Financing
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!